GlassScriptPhysician profile
Lorenzo G Gallon
NPI 1427093848
$120,002.48
in general payments reported to CMS, 2019-2025
14 companies · $5,856 in 2025
The $5,856 reported for 2025 was more than what 94% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79K · 2020: $9,250 · 2021: $8,683 · 2022: $5,534 · 2023: $1,375 · 2024: $10K · 2025: $5,856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Travel and Lodging: $1,260 · Food and Beverage: $524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,737.50 |
| Travel and Lodging | $1,260.49 |
| Food and Beverage | $524.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $78,311.61 | 2019-2022 | |
| Argenx US, INC. | $13,262.50 | 2022-2025 | Vyvgart Hytrulo |
| Calliditas Therapeutics US INC. | $8,220.49 | 2024-2025 | Tarpeyo |
| Immucor, INC. | $5,400.00 | 2021 | |
| Gilead Sciences, INC. | $5,146.39 | 2019 | |
| Mallinckrodt Enterprises LLC | $4,285.00 | 2019 | |
| Horizon Therapeutics Plc | $2,075.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,000.00 | 2021 | |
| Baxter Healthcare | $862.00 | 2021 | |
| Glaxosmithkline, LLC. | $275.00 | 2023 | Benlysta |
| Sanofi-Aventis U.S. LLC | $164.49 | 2024-2025 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorenzo Gallon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.